Why would anyone expect the SP to increase significantly on this ann? It is dosing a first patient. It’s a great box to tick but that’s all it is.
As others have said, the only things that will get us moving are further great trial results, a b-cell platform deal (which should put a higher floor under the SP before the main event(s) or some commercial partnership deal with BP to fund future trials etc.
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-83
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $143.0K | 10.33M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 19360226 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 5956728 | 12 |
View Market Depth
| Last trade - 12.00pm 18/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |